CMMB (Chemomab Therapeutics) Cash-to-Debt : 56.66 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Chemomab Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2024 was 56.66.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Chemomab Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Chemomab Therapeutics's Cash-to-Debt or its related term are showing as below:

CMMB' s Cash-to-Debt Range Over the Past 10 Years
Min: 27.33 Med: 178.31 Max: 190.43
Current: 56.66

During the past 4 years, Chemomab Therapeutics's highest Cash to Debt Ratio was 190.43. The lowest was 27.33. And the median was 178.31.

CMMB's Cash-to-Debt is ranked better than
73.3% of 1487 companies
in the Biotechnology industry
Industry Median: 6.4 vs CMMB: 56.66

Chemomab Therapeutics Cash-to-Debt Historical Data

The historical data trend for Chemomab Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Chemomab Therapeutics Cash-to-Debt Chart

Chemomab Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

27.33

178.31

186.42

50.47

Chemomab Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial														N/A	50.47	40.71	35.35	56.66

Competitive Comparison of Chemomab Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Chemomab Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chemomab Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Chemomab Therapeutics's Cash-to-Debt falls into.

Chemomab Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Chemomab Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	19.784	/	(0.076	+	0.316)
	=	50.47

Chemomab Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	19.378	/	(0.112	+	0.23)
	=	56.66

Chemomab Therapeutics (NAS:CMMB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Chemomab Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Chemomab Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Chemomab Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (NAS:CMMB) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

2QV0:Germany

Address

Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002

Website

https://www.chemomab.com

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Executives

Orbimed Israel Biofund Gp Limited Partnership	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
George Adi Mor	director, 10 percent owner, officer: Chief Executive Officer	15 KAFRISIN ST., TEL AVIV L3 6901658
Neil Harris Cohen	director	C/O ANCHIANO THERAPEUTICS LTD., ONE KENDALL SQ., BLDG 1400E, STE 14-105, CAMBRIDGE MA 02139
Matthew Bejosa Frankel	officer: Chief Medical Officer	672 PROSPECT AVE., PRINCETON NJ 08540
Jill M. Quigley	director	TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Joel Michael Maryles	director	5 ATZMON ST., HASHMONAIM L3 7312700
Donald Marvin	officer: Executive VP, CFO & COO	2094 LOST CANYON RANCH CT, CASTLE ROCK CO 80104
Dale R Pfost	director, officer: Chief Executive Officer	ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Nissim Darvish	director	C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Peter Thiel	10 percent owner	9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Sigal Fatal	officer: Chief Financial Officer	16 KANFEY NESHARIM ST., RAMAT GAN L3 5235716
Arnon Aharon	officer: Chief Medical Officer	12 YAVNE ST., TEL AVIV L3 6579116
Alan Charles Moses	director	C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Stephen P Squinto	director	C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Orbimed Israel Gp Ltd.	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629